EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modifying the Secretome of Mesenchymal Stem Cells Prolongs the Regenerative Treatment Window for Encephalopathy of Prematurity

Josine E G Vaes, Suzanne M Onstwedder, Chloe Trayford, Eva Gubbins, Mirjam Maas, Sabine H van Rijt iD, Cora H Nijboer

International Journal of Molecular Sciences · 12.06.2024 · 25 (12) · 6494

DOI: 10.3390/ijms25126494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.06.2024. Verfasst von Josine E G Vaes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht Universit…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Scientific Research, Dutch Province of Limburg, Brain Foundation the Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical treatment options to combat Encephalopathy of Prematurity (EoP) are still lacking. We, and others, have proposed (intranasal) mesenchymal stem cells (MSCs) as a potent therapeutic strategy to boost white matter repair in the injured preterm brain. Using a double-hit mouse model of diffuse white matter injury, we previously showed that the efficacy of MSC treatment was time dependent, with a significant decrease in functional and histological improvements after the postponement of cell administration. In this follow-up study, we aimed to investigate the mechanisms underlying this loss of therapeutic efficacy. Additionally, we optimized the regenerative potential of MSCs by means of genetic engineering with the transient hypersecretion of beneficial factors, in order to prolong the treatment window. Though the cerebral expression of known chemoattractants was stable over time, the migration of MSCs to the injured brain was partially impaired. Moreover, using a primary oligodendrocyte (OL) culture, we showed that the rescue of injured OLs was reduced after delayed MSC coculture. Cocultures of modified MSCs, hypersecreting IGF1, LIF, IL11, or IL10, with primary microglia and OLs, revealed a superior treatment efficacy over naïve MSCs. Additionally, we showed that the delayed intranasal administration of IGF1-, LIF-, or IL11-hypersecreting MSCs, improved myelination and the functional outcome in EoP mice. In conclusion, the impaired migration and regenerative capacity of intranasally applied MSCs likely underlie the observed loss of efficacy after delayed treatment. The intranasal administration of IGF1-, LIF-, or IL11-hypersecreting MSCs, is a promising optimization strategy to prolong the window for effective MSC treatment in preterm infants with EoP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsMiceSecretomeDisease Models, AnimalOligodendrogliaHumansCoculture TechniquesMicrogliaMice, Inbred C57BL

Stichwörter der Autor:innen

Encephalopathy of Prematurityadenoviruscell migrationcellular therapycentral nervous systemexperimental modelsgliamesenchymal stem cellsoligodendrocytespreterm birth

Autor:innen und Institutionen

  • Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3508 AB Utrecht, The Netherlands.
  • Department of Neonatology, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3508 AB Utrecht, The Netherlands.
  • Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, 6229 ER Maastricht, The Netherlands.

ORCID-Profile: Sabine H van Rijt

Förderung

  • Netherlands Organization for Scientific Research
  • Dutch Province of Limburg
  • Brain Foundation the Netherlands
  • Brain Foundation
  • The Netherlands Organization for Scientific Research

Zitieren

APA

Vaes, J. E. G., Onstwedder, S. M., Trayford, C., Gubbins, E., Maas, M., van Rijt, S. H., & Nijboer, C. H. (2024). Modifying the Secretome of Mesenchymal Stem Cells Prolongs the Regenerative Treatment Window for Encephalopathy of Prematurity. International Journal of Molecular Sciences, 25(12), 6494. https://doi.org/10.3390/ijms25126494

Vancouver

Vaes JEG, Onstwedder SM, Trayford C, Gubbins E, Maas M, van Rijt SH, et al. Modifying the Secretome of Mesenchymal Stem Cells Prolongs the Regenerative Treatment Window for Encephalopathy of Prematurity. International Journal of Molecular Sciences. 2024;25(12):6494. doi:10.3390/ijms25126494

BibTeX
@article{Vaes2024,
  author = {Vaes, Josine E G and Onstwedder, Suzanne M and Trayford, Chloe and Gubbins, Eva and Maas, Mirjam and van Rijt, Sabine H and Nijboer, Cora H},
  title = {Modifying the Secretome of Mesenchymal Stem Cells Prolongs the Regenerative Treatment Window for Encephalopathy of Prematurity},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {6494},
  doi = {10.3390/ijms25126494}
}
Kostenlos starten →